This is what the news should sound like. The biggest stories of our time, told by the best journalists in the world. Hosted by Michael Barbaro and Sabrina Tavernise. Twenty minutes a day, five days a week, ready by 6 a.m. Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. Listen to this podcast in New York Times Audio, our new iOS app for news subscribers. Download now at ...
…
continue reading
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
S6 Ep35: Biosimilars Policy Roundup for July 2024—Podcast Edition
MP3•Episode home
Manage episode 432414157 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Show notes
1. FDA Approves Samsung Bioepis’ Pyzchiva, a Biosimilar to Stelara
2. Ahzantive Receives FDA Approval as New Eylea Biosimilar
3. FDA Approves Epysqli as Second Soliris Biosimilar
4. BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
5. Biosimilars and Employers: Strategies for Success
6. Learning the Lingo of Biologics and Biosimilars Is Critical
7. Singapore Experience Shows Benefits of Value-Driven Strategies in Generating Biosimilar Savings
8. Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch
2. Ahzantive Receives FDA Approval as New Eylea Biosimilar
3. FDA Approves Epysqli as Second Soliris Biosimilar
4. BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
5. Biosimilars and Employers: Strategies for Success
6. Learning the Lingo of Biologics and Biosimilars Is Critical
7. Singapore Experience Shows Benefits of Value-Driven Strategies in Generating Biosimilar Savings
8. Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch
149 episodes
MP3•Episode home
Manage episode 432414157 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Show notes
1. FDA Approves Samsung Bioepis’ Pyzchiva, a Biosimilar to Stelara
2. Ahzantive Receives FDA Approval as New Eylea Biosimilar
3. FDA Approves Epysqli as Second Soliris Biosimilar
4. BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
5. Biosimilars and Employers: Strategies for Success
6. Learning the Lingo of Biologics and Biosimilars Is Critical
7. Singapore Experience Shows Benefits of Value-Driven Strategies in Generating Biosimilar Savings
8. Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch
2. Ahzantive Receives FDA Approval as New Eylea Biosimilar
3. FDA Approves Epysqli as Second Soliris Biosimilar
4. BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
5. Biosimilars and Employers: Strategies for Success
6. Learning the Lingo of Biologics and Biosimilars Is Critical
7. Singapore Experience Shows Benefits of Value-Driven Strategies in Generating Biosimilar Savings
8. Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch
149 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.